Genomic Health, Inc. (NASDAQ:GHDX) – Research analysts at Jefferies Group cut their FY2017 earnings estimates for Genomic Health in a note issued to investors on Thursday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings of ($0.09) per share for the year, down from their prior estimate of $0.01. Jefferies Group currently has a “Hold” rating and a $34.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/13/fy2017-eps-estimates-for-genomic-health-inc-cut-by-jefferies-group-ghdx.html.

A number of other analysts have also recently commented on the stock. Cowen and Company reiterated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Canaccord Genuity reissued a “buy” rating and issued a $35.00 target price on shares of Genomic Health in a report on Wednesday, September 27th. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a report on Thursday, August 3rd. Finally, ValuEngine downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $32.00.

Genomic Health (NASDAQ:GHDX) opened at $29.17 on Monday. Genomic Health has a 1-year low of $26.37 and a 1-year high of $34.02.

In other news, insider Kimberly J. Popovits sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $31.00, for a total transaction of $155,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,379 shares of company stock worth $676,131. Insiders own 46.20% of the company’s stock.

Several hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its stake in shares of Genomic Health by 0.6% during the 1st quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after purchasing an additional 500 shares during the last quarter. American International Group Inc. raised its stake in Genomic Health by 7.1% in the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock valued at $362,000 after buying an additional 765 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of Genomic Health by 5.6% in the first quarter. TIAA CREF Investment Management LLC now owns 71,233 shares of the medical research company’s stock valued at $2,243,000 after purchasing an additional 3,808 shares during the period. Legal & General Group Plc increased its holdings in shares of Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 2,038 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Genomic Health by 8.8% in the first quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock valued at $49,256,000 after purchasing an additional 126,807 shares during the period. Institutional investors and hedge funds own 89.13% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.